Swiss CDMO Lonza announced this week that it would be acquiring Synaffix, a Netherlands-based ADC-focused biotech.
Under the terms of the agreement, Lonza will pay an initial $107 million in cash and up to $64 million in milestones to wholly acquire Synaffix and its technology platform, which includes an advanced payload and site-specific linker technologies.
Synaffix, established in 2010, operated mainly under a technology out-licensing model, offering its clinical-stage platform capabilities. Its platform, which was awarded Best ADC Platform Technology at World ADC Awards ceremony in 2020, uses the company's proprietary GlycoConnect, HydraSpace and toxSYN technologies to improve the efficacy and tolerability of ADCs.
Peter van de Sande, CEO of Synaffix, expressed his enthusiasm about the collaboration, stating, "With the support of Lonza, we can accelerate technology innovations in bioconjugates beyond cytotoxic ADCs. We are excited to collaborate closely with our colleagues at Lonza to empower the development of promising medicines for patients in need."
